Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEUS: SAR442168 versus placebo in primary progressive multiple sclerosis
NL-OMON54188Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing SAR442168 with Placebo (2 arms). Primary endpoint: Time to onset of confirmed disability progression. Started May 2022; status: recruiting.
02
Drugs
tolebrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON54188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54188.